Amgen jolts to record-high after hiking FY forecasts, Q2 results beat

** Amgen AMGN.O shares jump 6.5% to all-time high of $415.51 in morning trading

** The stock's previous 52-week high was $398

** The Pharma major late Tuesday reported Q2 revenue of $10.1 billion, easily surpassing Wall Street estimates of $9.42 billion

** Q2 adj. EPS - $6.29 per share; analysts on avg expected $5.62, according to data compiled by LSEG

** AMGN also hiked FY forecasts for profit and revenue

** Results driven by strong sales of Repatha, Evenity and rare disease drugs, while Amgen advances its experimental obesity treatment MariTide

** Including session's move, AMGN stock was up 26% YTD